查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1678517

全球抗體藥物複合體契約製造市場：市場規模、佔有率、趨勢分析（按連接體、按適應症、按地區）、按細分市場預測（2025-2030 年）

Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Analysis Report By Linker (Cleavable, Non-cleavable), By Condition (Myeloma, Lymphoma, Breast Cancer), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

抗體藥物複合體契約製造市場的成長和趨勢：

根據Grand View Research, Inc.的最新報告，全球抗體藥物複合體契約製造市場規模預計到2030年將達到165.5億美元，2025年至2030年複合年成長率為10.99%。

推動該行業成長的因素包括抗體藥物複合體(ADC) 的複雜性、抗體療法研究的不斷增加以及癌症發病率的上升，這些都增加了對契約製造的需求。疫情期間，癌症臨床試驗一度暫停。但由於病情嚴重，臨床試驗重新開啟。根據 IQVIA 2022 年腫瘤學趨勢報告，癌症臨床試驗的數量正在增加。

根據 IQVIA 的報告，2016 年至 2021 年間，腫瘤臨床試驗將增加 56%。由於全球癌症發生率不斷上升，預計臨床試驗的數量還將進一步增加。預計這將支持 ADC 開發和製造活動，並為疫情後的行業成長提供支援。抗體藥物複合體在治療癌症方面非常有效，因為它們只針對癌細胞而不會影響體內的健康細胞。因此，一些生物製藥公司正在大力資助 ADC 相關研究。

例如，2022 年 10 月，Mablink Biosciences 在 A 輪資金籌措中籌集了 3,100 萬美元，用於擴展其抗體藥物複合體產品線。因此，對 ADC 研發的大量投資預計將提高 ADC 的可用性，並支持未來幾年對 ADC契約製造的需求。 2021年9月，美國FDA加速核准ADC藥物tisotumab vedotin-tftv，用於治療病情進展或化療後復發或轉移性子宮頸癌成年患者。預計此類核准將在未來幾年推動對 ADC契約製造服務的需求。

抗體藥物複合體契約製造市場：分析概述

  • 根據症狀，這些癌症包括骨髓瘤、淋巴瘤、乳癌等。 2024 年，骨髓瘤領域佔據市場主導地位，收益佔有率最大，為 49.61%。預計淋巴瘤部分在預測期內將呈現最快的複合年成長率。
  • 根據接頭，市場分為可裂解接頭和不可裂解接頭。可裂解連接體部分在 2024 年佔據市場最大收益佔有率，達 56.1%。
  • 預計北美抗體藥物複合體契約製造市場在預測期內將實現最快的複合年成長率。
  • 2024 年亞太地區抗體藥物複合體契約製造市場佔據主導地位，收入佔有率最大，為 40.93%。該地區的成長主要歸功於支持性監管改革，尤其是印度和中國等國家，以及低成本勞動力。

目錄

第1章 分析方法及範圍

第 2 章執行摘要

第 3 章抗體藥物複合體(ADC)契約製造市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 技術格局
  • 定價模式分析
  • 產業生態系統分析
  • 市場分析工具
    • 波特五力分析
    • PESTEL 分析
    • COVID-19影響分析

第 4 章抗體藥物複合體(ADC)契約製造市場：按適應症進行的估計和趨勢分析

  • 抗體藥物複合體(ADC)契約製造市場（按適應症）：細分儀表板
  • 抗體藥物複合體(ADC)契約製造市場（按適應症）：變異分析
  • 各州，2018-2030 年
  • 骨髓瘤
  • 淋巴瘤
  • 乳癌
  • 其他

第 5 章抗體藥物複合體(ADC)契約製造市場：Linker 的估計與趨勢分析

  • 抗體藥物複合體(ADC)契約製造市場（按 Linker 分類）：細分儀表板
  • 抗體藥物複合體(ADC)契約製造市場（按 Linker 分類）：變異分析
  • Rinker，2018-2030
  • 可裂解接頭
  • 不可裂解接頭

第6章抗體藥物複合體(ADC)契約製造市場：按地區估計和趨勢分析

  • 各地區市場佔有率分析（2024 年及 2030 年）
  • 市場儀表板：按地區
  • 全球市場概況：按地區
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 丹麥
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 泰國
    • 韓國
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 市場參與企業分類
    • 市場領導
    • 新興企業
  • 公司市場佔有率/估值分析（2024 年）
  • 公司簡介
    • Sterling
    • Recipharm AB
    • Lonza
    • Catalent, Inc.
    • Sartorius AG
    • Wuxi Biologics
    • Samsung Biologics
    • Piramal Group（Piramal Pharma Solutions）
    • AbbVie, Inc.（AbbVie Contract Manufacturing）
    • Merck KGaA
Product Code: GVR-4-68039-623-5

Antibody Drug Conjugates Contract Manufacturing Market Growth & Trends:

The global antibody drug conjugates contract manufacturing market size is expected to reach USD 16.55 billion by 2030, registering a CAGR of 10.99% from 2025 to 2030, according to a new report by Grand View Research, Inc. The factors driving the industry growth include the complex nature of antibody drug conjugates (ADCs) contributing to the demand for contract manufacturing, the increasing number of research on antibody therapies, and the rise in cancer incidence. During the pandemic, the clinical trials for cancer were stopped for a short period. However, owing to the severity of the disease, the trials were started again. As per the IQVIA Oncology Trends Report 2022, the number of clinical trials for cancer is growing.

The IQVIA report states that there was a 56% increase in oncology clinical trials between 2016 and 2021. This number of clinical studies is expected to rise even further owing to the growing prevalence of cancer worldwide. This is expected to support the ADC development and manufacturing activities, thus supporting industry growth post-pandemic. Antibody drug conjugates have high efficiency in treating cancer as it only targets the cancerous cells and does not affect the healthy cells of the body. As a result, several biopharmaceutical companies have received significant funding for ADC-related research.

For instance, in October 2022, Mablink Bioscience, raise USD 31 million from Series A funding to build its antibody drug conjugate pipeline. Thus, heavy investments in the R&D of ADCs are expected to improve their availability in the coming years and thus support the demand for ADC contract manufacturing. In September 2021, the U.S. FDA provided accelerated approval for ADC tisotumab vedotin-tftv for treating adult patients with recurrent or metastatic cervical cancer with disease progression or after chemotherapy. Such approvals, in the coming years, are expected to boost the demand for contract manufacturing services for ADC.

Antibody Drug Conjugates Contract Manufacturing Market Report Highlights:

  • Based on condition, the market includes myeloma, lymphoma, breast cancer and others. The myeloma segment led the market with the largest revenue share of 49.61% in 2024. The lymphoma segment is anticipated to witness the fastest CAGR during the forecast period.
  • Based on linker, the market is segmented into cleavable linkers and non-cleavable linkers. The cleavable linkers segment led the market with the largest revenue share of 56.1% in 2024.
  • The antibody drug conjugates contract manufacturing market in North America is expected to witness the fastest CAGR over the forecast period.
  • Asia Pacific antibody drug conjugates contract manufacturing market dominated the market with the largest revenue share of 40.93% in 2024. The regional growth is primarily owing to supportive regulatory reforms, especially in countries such as India & China, and low-cost labor.

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates And Forecast Timeline
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Parent Market Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives
    • 1.10.1. Objective-1
    • 1.10.2. Objective-2
    • 1.10.3. Objective-3

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Antibody Drug Conjugates (ADC) Contract Manufacturing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising Incidence of Cancer
      • 3.2.1.2. High Cost of Manufacturing ADC and Challenges Associated With Manufacturing Contributing to the Demand for Contract Manufacturing
      • 3.2.1.3. Increasing R&D Activities on ADCs
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Quality Issues While Outsourcing
      • 3.2.2.2. Limited Outsourcing Opted by Big Biopharma Companies
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Industry Ecosystem Analysis
  • 3.6. Market Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Antibody Drug Conjugates (ADC) Contract Manufacturing Market: Condition Estimates & Trend Analysis

  • 4.1. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, By Condition: Segment Dashboard
  • 4.2. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, By Condition: Movement Analysis
  • 4.3. Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates & Forecasts, By Condition, 2018 - 2030 (USD Million)
  • 4.4. Myeloma
    • 4.4.1. Myeloma Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.5. Lymphoma
    • 4.5.1. Lymphoma Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.6. Breast Cancer
    • 4.6.1. Breast Cancer Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 5. Antibody Drug Conjugates (ADC) Contract Manufacturing Market: Linker Estimates & Trend Analysis

  • 5.1. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, By Linker: Segment Dashboard
  • 5.2. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, By Linker: Movement Analysis
  • 5.3. Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates & Forecasts, By Linker, 2018 - 2030 (USD Million)
  • 5.4. Cleavable Linker
    • 5.4.1. Cleavable Linker Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 5.5. Non-Cleavable Linker
    • 5.5.1. Non-Cleavable Linker Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 6. Antibody Drug Conjugates (ADC) Contract Manufacturing Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. North America
    • 6.4.1. North America Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Competitive Scenario
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Competitive Scenario
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Competitive Scenario
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Competitive Scenario
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Competitive Scenario
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Competitive Scenario
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Competitive Scenario
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Sweden
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Competitive Scenario
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Denmark
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Competitive Scenario
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Competitive Scenario
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Competitive Scenario
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Competitive Scenario
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Thailand
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Competitive Scenario
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Competitive Scenario
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Australia
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Competitive Scenario
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Competitive Scenario
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Competitive Scenario
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Competitive Scenario
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Competitive Scenario
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Competitive Scenario
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Competitive Scenario
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Market Participant Categorization
    • 7.1.1. Market Leaders
    • 7.1.2. Emerging Players
  • 7.2. Company Market Share/Assessment Analysis, 2024
  • 7.3. Company Profiles
    • 7.3.1. Sterling
      • 7.3.1.1. Company Overview
      • 7.3.1.2. Financial Performance
      • 7.3.1.3. Service Benchmarking
      • 7.3.1.4. Strategic Initiatives
    • 7.3.2. Recipharm AB
      • 7.3.2.1. Company Overview
      • 7.3.2.2. Financial Performance
      • 7.3.2.3. Service Benchmarking
      • 7.3.2.4. Strategic Initiatives
    • 7.3.3. Lonza
      • 7.3.3.1. Company Overview
      • 7.3.3.2. Financial Performance
      • 7.3.3.3. Service Benchmarking
      • 7.3.3.4. Strategic Initiatives
    • 7.3.4. Catalent, Inc.
      • 7.3.4.1. Company Overview
      • 7.3.4.2. Financial Performance
      • 7.3.4.3. Service Benchmarking
      • 7.3.4.4. Strategic Initiatives
    • 7.3.5. Sartorius AG
      • 7.3.5.1. Company Overview
      • 7.3.5.2. Financial Performance
      • 7.3.5.3. Service Benchmarking
      • 7.3.5.4. Strategic Initiatives
    • 7.3.6. Wuxi Biologics
      • 7.3.6.1. Company Overview
      • 7.3.6.2. Financial Performance
      • 7.3.6.3. Service Benchmarking
      • 7.3.6.4. Strategic Initiatives
    • 7.3.7. Samsung Biologics
      • 7.3.7.1. Company Overview
      • 7.3.7.2. Financial Performance
      • 7.3.7.3. Service Benchmarking
      • 7.3.7.4. Strategic Initiatives
    • 7.3.8. Piramal Group (Piramal Pharma Solutions)
      • 7.3.8.1. Company Overview
      • 7.3.8.2. Financial Performance
      • 7.3.8.3. Service Benchmarking
      • 7.3.8.4. Strategic Initiatives
    • 7.3.9. AbbVie, Inc. (AbbVie Contract Manufacturing)
      • 7.3.9.1. Company Overview
      • 7.3.9.2. Financial Performance
      • 7.3.9.3. Service Benchmarking
      • 7.3.9.4. Strategic Initiatives
    • 7.3.10. Merck KGaA
      • 7.3.10.1. Company Overview
      • 7.3.10.2. Financial Performance
      • 7.3.10.3. Service Benchmarking
      • 7.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 Information Procurement
  • Table 2 Primary Research Pattern
  • Table 3 Market Research Approaches
  • Table 4 Value Chain-Based Sizing & Forecasting
  • Table 5 Market Formulation & Validation
  • Table 6 Antibody Drug Conjugates (ADC) Contract Manufacturing, Market Segmentation
  • Table 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Table 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Table 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Table 10 Porter's Five Forces Analysis
  • Table 11 Regional Marketplace: Key Takeaways
  • Table 12 Global Antibody Drug Conjugates (ADC) Contract Manufacturing, for Myeloma, 2018 - 2030 (USD Million)
  • Table 13 Global Antibody Drug Conjugates (ADC) Contract Manufacturing, for Lymphoma, 2018 - 2030 (USD Million)
  • Table 14 Global Antibody Drug Conjugates (ADC) Contract Manufacturing, for Breast Cancer, 2018 - 2030 (USD Million)
  • Table 15 Global Antibody Drug Conjugates (ADC) Contract Manufacturing, for Others, 2018 - 2030 (USD Million)
  • Table 16 Global Antibody Drug Conjugates (ADC) Contract Manufacturing, for Cleavable Linker, 2018 - 2030 (USD Million)
  • Table 17 Global Antibody Drug Conjugates (ADC) Contract Manufacturing, for Non-cleavable Linker, 2018 - 2030 (USD Million)
  • Table 18 Regional Outlook, 2024 & 2030
  • Table 19 North America Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 20 U.S. Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 21 Canada Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 22 Mexico Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 23 Europe Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 24 UK Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 25 Germany Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 26 France Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 27 Italy Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 28 Spain Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 29 Denmark Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 30 Sweden Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 31 Norway Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 33 India Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 34 China Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 35 Japan Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 36 South Korea Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 37 Australia Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 38 Thailand Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 39 Latin America Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 40 Brazil Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 41 Argentina Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 42 MEA Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 43 South Africa Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 44 Saudi Arabia Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 45 UAE Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 46 Kuwait Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 List of Secondary Sources
  • Fig. 2 List of Abbreviations
  • Fig. 3 Global Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 4 Global Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 5 Global Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Region, 2018 - 2030 (USD Million)
  • Fig. 6 North America Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Country, 2018 - 2030 (USD Million)
  • Fig. 7 North America Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 8 North America Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 9 U.S. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 10 U.S. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 11 Canada Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 12 Canada Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 13 Mexico Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 14 Mexico Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 15 Europe Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Country, 2018 - 2030 (USD Million)
  • Fig. 16 Europe Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 17 Europe Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 18 Germany Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 19 Germany Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 20 UK Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 21 UK Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 22 France Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 23 France Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 24 Italy Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 25 Italy Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 26 Spain Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 27 Spain Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 28 Denmark Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 29 Denmark Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 30 Sweden Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 31 Sweden Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 32 Norway Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 33 Norway Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 34 Asia Pacific Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Country, 2018 - 2030 (USD Million)
  • Fig. 35 Asia Pacific Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 36 Asia Pacific Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 37 China Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 38 China Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 39 Japan Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 40 Japan Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 41 India Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 42 India Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 43 South Korea Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 44 South Korea Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 45 Australia Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 46 Australia Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 47 Thailand Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 48 Thailand Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 49 Latin America Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Country, 2018 - 2030 (USD Million)
  • Fig. 50 Latin America Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 51 Latin America Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 52 Brazil Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 53 Brazil Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 54 Argentina Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 55 Argentina Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 56 Middle East & Africa Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Country, 2018 - 2030 (USD Million)
  • Fig. 57 Middle East & Africa Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 58 Middle East & Africa Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 59 South Africa Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 60 South Africa Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 61 Saudi Arabia Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 62 Saudi Arabia Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 63 UAE Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 64 UAE Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 65 Kuwait Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 66 Kuwait Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)